VIDEO: EYP-1901 shows noninferiority to aflibercept in wet AMD
KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Ashkan M. Abbey, MD, discusses 1-year results from the phase 2 DAVIO 2 clinical trial investigating EYP-1901 in previously treated wet age-related macular degeneration.
According to Abbey, the trial achieved its primary endpoint of noninferiority in change in best corrected visual acuity with EYP-1901 (vorolanib intravitreal insert, EyePoint Pharmaceuticals) compared with aflibercept between weeks 28 and 32. Patients who received EYP-1901 also required significantly fewer treatments, demonstrating a positive reduction in treatment burden.
“These patients were able to have maintenance of stable, good visual acuity while also stabilizing and controlling their anatomy quite well after receiving EYP-1901,” Abbey said. “Also, the safety profile is very good so far, so we are looking forward to future data in phase 3.”
Collapse
Abbey A, et al. DAVIO 2: Year 1 results from a phase 2, multicenter, non-inferiority trial of EYP-1901 (vorolanib intravitreal insert) versus aflibercept for previously-treated wet age-related macular degeneration. Presented at: Retina 2025; Jan. 18-24, 2025; Koloa, Hawaii.
Read more about